Similar to GW Pharmaceuticals, Celator Pharmaceuticals Inc. (NASDAQ: CPXX) is coming off positive results from recent trials and seeing shares soar (from $2 to over $10). Investors are expecting a sizable reaction from its clinical trial results. Earlier in March, Celator announced positive results from its Phase 3 trial of Vyxeos piposome for injection (also known as CPX-351) in patients with high-risk (secondary) acute myeloid leukemia. Based on these results the company expects to submit a NDA for Vyxeos with the FDA later this year, and submit a Marketing Authorization Application with the European Medicines Agency in the first quarter of 2017.
Celator close most recently at $11.05. The consensus price target is $18.33, and the 52-week range is $1.12 to $12.73. This company currently does not have any revenue, and analysts do not expect sales of more than $100 million until 2019.
After it announced results from OPuS-2 for the treatment of hereditary angioedema (HAE) attacks earlier in the first quarter of 2016, BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) got crushed. Unfortunately, the company said that this treatment failed to demonstrate a statistically significantly lower mean attack rate than a placebo. This was a liquid-filled soft gel formulation for the prophylactic treatment of HAE.
The company did say that oral administration of avoralstat in OPuS-2 was generally safe and well tolerated. It also noted that the adverse event profile was similar to that for the placebo, and no safety signals were observed. BioCryst plans to release its Phase 2 data for BCX7353 in the treatment of HAE by the end of 2016, which could either be incredibly positive or another let down. It seems that not all investors are writing off BioCryst yet.
BioCryst closed at $2.76, within a 52-week range of $1.63 to $16.83. The consensus price target is $6.56. Consensus estimates call for revenues of $21.5 million for the full year.
In the fourth quarter of 2016, Galena Biopharma Inc. (NASDAQ: GALE) expects to report data from its Phase 2b randomized, combination trial with NeuVax and trastuzumab. At that time, this company expects to present interim safety data as well as patient immunology data on the A24 and A25 human leukocyte antigen status in the fourth quarter. What stands out with this trial is that trastuzumab is one of the highest revenue drugs in the world and it better known as Herceptin. Positive results in conjunction with a best-selling drug could skyrocket the stock — and of course a negative outcome could prove costly.
Shares of Galena closed at $1.06. The stock has a consensus price target of $3.90 and a 52-week range of $0.59 to $2.39. In 2015, this company had annual revenues totaling $9.73 million, but revenue is not expected to ramp up until 2019.